Next-Generation Drug Delivery Nanocarriers in Human Osteosarcoma Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (28 March 2024) | Viewed by 122
Special Issue Editors
Interests: nanotechnology and nanoparticles; drug delivery; active targeting; bone delivery; ocular delivery; cancer therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Osteosarcoma is the most common primary metastatic bone cancer in 10–20-year-old patients, and is also prevalent in elderlies. Currently, chemotherapy is essential in the treatment of osteosarcoma, but it is limited due to the side effects and development of drug resistance. Next-generation nanotechnology is currently under study as a potential strategy to overcome these drawbacks. Indeed, through the functionalization of chemotherapeutic agents with smart nanocarrier properties, drug clearance, circulation time, and drug concentration at tumor sites can be improved, thus enhancing therapeutic efficacy and reducing side effects. Nanoparticles, liposomes, microspheres, and cements are only some of the drug delivery systems that have attracted the attention of researchers in recent years. The aim of this Special Issue is to highlight recent advances in the field of next-generation nanotechnology for the treatment of osteosarcoma. Thus, we are pleased to invite you to publish your research in this Special Issue of Pharmaceutics, “Next-Generation Drug Delivery Nanocarriers in Human Osteosarcoma Treatment”. The submission of original research papers and review articles is welcome.
We look forward to receiving your contributions.
Prof. Dr. Marina Gallarate
Dr. Giulia Chindamo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- human osteosarcoma
- nanotechnology
- drug delivery systems
- target therapy
- nanocarriers
- bone diseases
- nanoparticles
